Dyne Therapeutics

Today we reported financial results for the third quarter of 2024 and provided a corporate update. Read here: https://bit.ly/4hHbW5T #investors #biotechnology #healthcare

We’re just a few months away from #RareDiseaseDay 2025. If you’re a healthcare professional, join Rare Disease Day's webinar on November 13 to learn more about rare diseases and help raise awareness: https://bit.ly/3BVB0FQ

We look forward to presenting at upcoming investor conferences this month. Learn more: https://bit.ly/3zHnp4e $DYN

We’re proud to sponsor the upcoming Little Steps Association for Duchenne and Becker Muscular Dystrophy patients bi-annual conference. Learn more about the organization: https://bit.ly/40weT32

We’re joining clinicians, researchers, and individuals living with Duchenne at the Action Duchenne Annual International Conference to discuss the latest advances in #DMD research. Check out this year’s agenda and be sure to catch us during the industry Q&A: https://bit.ly/3NTiArW #Duchenne #biotechnology

Honoring the unsung heroes this #NationalFamilyCaregiversMonth, who tirelessly support their loved ones with muscle diseases. Their strength inspires us. Explore the powerful stories from our community and how they live with and manage serious muscle diseases like #DMD, #DM1 and #FSHD: https://bit.ly/3MmFSWQ

If you’re attending the 18th International Congress on Neuromuscular Diseases (ICNMD 2024), don’t miss the presentations on data from our ACHIEVE and DELIVER trials in #DM1 and #DMD. Learn more about the congress and check out the program: https://icnmd.org/ #ICNMD2024

With our FORCE? platform, we’re tackling delivery challenges to muscle, advancing clinical programs for DM1 and DMD, and our work in FSHD and Pompe disease. To learn more about our innovative approach, read the article by our Chief Scientific Officer Oxana Beskrovnaya where she shares the science behind the FORCE platform and our mission to transform lives. #RareDiseases #Innovation #Biotech?

Meet James Bilotta, who recently joined Dyne as our chief digital information officer! James brings a wealth of experience in leading digital transformations and implementation of technology strategies that facilitate growth and success on a global scale. Join us in welcoming James to our team of #Dynamos! #leadership #biotech

Have you watched the latest episode in our Joining Forces series? ? Pat Furlong, founding president and CEO of Parent Project Muscular Dystrophy, and Dyne’s Chief Medical Affairs Officer, Ashish Dugar, PhD, MBA, discuss the importance of involving and educating the community about clinical trials and the regulatory process. Watch the full video here: https://bit.ly/3zRSi6h ? Read more about this initiative in the journal Research Involvement and Engagement: https://bit.ly/4dMU8mW ? #patientadvocacy #patientcenteredresearch